Free Trial
→ SpaceX will crumble without these 5 companies (From InvestPub) (Ad)tc pixel Free BEAM Stock Alerts

Beam Therapeutics (BEAM) Financials

Beam Therapeutics logo
$30.50 +1.47 (+5.05%)
As of 10:29 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Beam Therapeutics

Annual Income Statements for Beam Therapeutics

This table shows Beam Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -91 -196 -371 -289 -133 -377 -80
Consolidated Net Income / (Loss)		 -78 -195 -371 -289 -133 -377 -80
Net Income / (Loss) Continuing Operations		 -78 -195 -371 -289 -133 -377 -80
Total Pre-Tax Income 		-78 -195 -371 -260 -131 -377 -80
Total Operating Income		 -75 -133 -392 -338 -176 -416 -384
Total Gross Profit		 0.02 0.02 52 61 378 64 140
Total Revenue		 0.02 0.02 52 61 378 64 140
Operating Revenue		 0.02 0.02 52 61 378 64 140
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 75 133 444 399 554 479 523
Selling, General & Admin Expense		 21 30 57 88 117 112 114
Research & Development Expense		 55 103 387 312 437 368 410
Total Other Income / (Expense), net		 -3.17 -62 22 78 45 39 304
Interest Expense		 -2.23 -1.05 0.01 -15 -47 -49 -44
Interest & Investment Income		 - - - - - - 255
Other Income / (Expense), net		 -5.40 -63 22 63 -1.35 -10 4.82
Income Tax Expense		 - 0.00 0.00 3.41 1.37 0.04 0.00
Basic Earnings per Share		 ($14.05) ($4.19) ($5.77) ($4.13) ($1.72) ($4.58) ($0.81)
Weighted Average Basic Shares Outstanding		 6.48M 46.73M 64.23M 70.02M 77.15M 82.31M 98.91M
Diluted Earnings per Share		 ($14.05) ($4.19) ($5.77) ($4.13) ($1.72) ($4.58) ($0.81)
Weighted Average Diluted Shares Outstanding		 6.48M 46.73M 64.23M 70.02M 77.15M 82.31M 98.91M
Weighted Average Basic & Diluted Shares Outstanding		 6.48M 46.73M 68.73M 72.40M 81.66M 83.69M 101.86M

Quarterly Income Statements for Beam Therapeutics

This table shows Beam Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -96 143 -99 -91 -97 -90 -108 -102 -113 244 -94
Consolidated Net Income / (Loss)		 -96 143 -99 -91 -97 -90 -108 -102 -113 244 -94
Net Income / (Loss) Continuing Operations		 -96 143 -99 -91 -97 -90 -108 -102 -113 244 -94
Total Pre-Tax Income 		-96 48 -99 -91 -97 -189 -108 -102 -113 244 -94
Total Operating Income		 -108 133 -104 -105 -107 -100 -119 -120 -127 -17 -107
Total Gross Profit		 17 316 7.41 12 14 30 7.47 8.47 9.70 114 32
Total Revenue		 17 316 7.41 12 14 30 7.47 8.47 9.70 114 32
Operating Revenue		 17 316 7.41 12 14 30 7.47 8.47 9.70 114 32
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 125 183 112 117 121 130 127 129 137 131 139
Selling, General & Admin Expense		 25 43 27 30 27 29 28 27 27 32 34
Research & Development Expense		 100 140 85 87 94 101 99 102 110 99 105
Total Other Income / (Expense), net		 12 11 5.46 14 9.84 9.68 11 18 14 262 13
Interest Expense		 -13 -12 -12 -14 -12 -11 -9.86 -12 -11 -11 -9.87
Other Income / (Expense), net		 -0.52 -0.76 -6.39 -0.31 -2.26 -1.25 1.12 5.56 3.18 -4.10 3.03
Basic Earnings per Share		 ($1.22) $1.91 ($1.21) ($1.11) ($1.17) ($1.09) ($1.23) ($1.00) ($1.10) $2.53 ($0.91)
Weighted Average Basic Shares Outstanding		 79.02M 77.15M 81.70M 82.31M 82.41M 82.31M 87.98M 102.00M 102.57M 98.91M 103.26M
Diluted Earnings per Share		 ($1.22) $1.91 ($1.21) ($1.11) ($1.17) ($1.09) ($1.23) ($1.00) ($1.10) $2.53 ($0.91)
Weighted Average Diluted Shares Outstanding		 79.02M 77.15M 81.70M 82.31M 82.41M 82.31M 87.98M 102.00M 102.57M 98.91M 103.26M
Weighted Average Basic & Diluted Shares Outstanding		 81.50M 81.66M 82.31M 82.42M 82.81M 83.69M 100.56M 101.16M 101.47M 101.86M 102.88M

Annual Cash Flow Statements for Beam Therapeutics

This table details how cash moves in and out of Beam Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -97 126 396 -327 199 -155 12
Net Cash From Operating Activities		 -72 -96 -66 23 -149 -347 -345
Net Cash From Continuing Operating Activities		 -72 -96 -66 23 -149 -347 -345
Net Income / (Loss) Continuing Operations		 -78 -195 -371 -289 -133 -377 -80
Consolidated Net Income / (Loss)		 -78 -195 -371 -289 -133 -377 -80
Depreciation Expense		 3.50 4.74 7.45 14 20 22 22
Amortization Expense		 -0.92 0.12 -0.08 -0.98 -30 -23 -16
Non-Cash Adjustments To Reconcile Net Income		 12 92 -109 378 109 129 -140
Changes in Operating Assets and Liabilities, net		 -8.17 2.20 406 -80 -116 -99 -131
Net Cash From Investing Activities		 -67 -100 -294 -461 72 185 -121
Net Cash From Continuing Investing Activities		 -66 -99 -294 -461 72 185 -121
Purchase of Property, Plant & Equipment		 -13 -16 -47 -49 -34 -8.95 -15
Acquisitions		 - - - - 0.00 0.00 -0.08
Purchase of Investments		 -130 -282 -777 -1,617 -984 -486 -1,210
Divestitures		 0.00 0.00 0.62 0.00 0.00 0.00 255
Sale and/or Maturity of Investments		 76 199 529 1,205 1,090 680 848
Net Cash From Financing Activities		 41 322 756 112 276 7.74 478
Net Cash From Continuing Financing Activities		 41 322 756 112 276 7.74 478
Repayment of Debt		 -0.46 -1.57 - -2.29 -2.25 -0.49 0.00
Repurchase of Common Equity		 -2.52 -2.06 -8.82 -0.19 0.00 0.00 0.00
Issuance of Common Equity		 0.00 320 757 111 273 2.62 473
Other Financing Activities, net		 0.19 3.16 7.51 2.73 6.13 5.60 4.77
Cash Interest Paid		 0.19 0.56 0.57 0.38 0.16 0.03 0.00

Quarterly Cash Flow Statements for Beam Therapeutics

This table details how cash moves in and out of Beam Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -63 267 -150 4.62 -62 53 244 -246 -14 27 -6.64
Net Cash From Operating Activities		 -90 135 -100 -83 -88 -76 -104 -76 -81 -83 -129
Net Cash From Continuing Operating Activities		 -90 135 -100 -83 -88 -76 -104 -76 -81 -83 -129
Net Income / (Loss) Continuing Operations		 -96 143 -99 -91 -97 -90 -108 -102 -113 244 -94
Consolidated Net Income / (Loss)		 -96 143 -99 -91 -97 -90 -108 -102 -113 244 -94
Depreciation Expense		 5.19 5.36 5.43 5.58 5.48 5.44 5.53 5.54 5.56 5.67 5.61
Amortization Expense		 -7.88 2.17 -6.58 -5.93 -5.62 5.03 -3.85 -4.62 -4.23 -3.26 -2.73
Non-Cash Adjustments To Reconcile Net Income		 35 7.81 35 33 31 21 25 15 45 -229 19
Changes in Operating Assets and Liabilities, net		 -26 -23 -35 -25 -22 -17 -22 10 -15 -101 -56
Net Cash From Investing Activities		 -10 98 -53 87 25 126 -125 -170 66 108 25
Net Cash From Continuing Investing Activities		 -10 98 -53 87 25 126 -125 -170 66 108 25
Purchase of Property, Plant & Equipment		 -7.95 -3.59 -2.44 -1.96 -1.58 -2.97 -3.07 -3.14 -5.01 -3.73 -2.23
Purchase of Investments		 -274 -53 -195 -134 -157 - -339 -334 -176 -361 -154
Sale and/or Maturity of Investments		 271 155 144 224 183 129 217 167 246 218 181
Net Cash From Financing Activities		 37 34 2.90 0.13 1.26 3.44 473 1.11 1.68 1.89 97
Net Cash From Continuing Financing Activities		 37 34 2.90 0.13 1.26 3.44 473 1.11 1.68 1.89 97
Repayment of Debt		 -0.40 -0.63 -0.18 -0.11 -0.20 - 0.00 - - - -0.81
Issuance of Debt		 - - - - - - 0.00 - - - 94
Issuance of Common Equity		 36 34 1.40 - 1.22 -0.00 473 -0.65 1.26 - 1.51
Other Financing Activities, net		 1.29 0.75 1.68 0.24 0.24 3.45 0.72 1.76 0.41 1.89 2.03
Cash Interest Paid		 0.03 0.02 0.01 0.01 0.01 - 0.00 - - - 0.00

Annual Balance Sheets for Beam Therapeutics

This table presents Beam Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 156 452 1,474 1,342 1,460 1,104 1,481
Total Current Assets		 95 308 1,273 1,093 1,211 878 1,269
Cash & Equivalents		 37 162 560 233 436 282 295
Short-Term Investments		 55 138 406 845 754 569 950
Prepaid Expenses		 2.70 8.65 7.36 15 21 27 23
Plant, Property, & Equipment, net		 24 39 84 116 125 111 105
Total Noncurrent Assets		 37 105 117 133 124 114 108
Other Noncurrent Operating Assets		 37 105 117 133 124 114 108
Total Liabilities & Shareholders' Equity		 156 452 1,474 1,342 1,460 1,104 1,481
Total Liabilities		 55 206 648 608 478 370 243
Total Current Liabilities		 29 102 213 224 206 182 97
Short-Term Debt		 - - - - - 0.00 2.71
Accounts Payable		 7.85 6.31 7.47 9.03 1.62 3.87 10
Accrued Expenses		 7.85 18 68 50 112 47 55
Current Deferred Revenue		 - 0.02 86 136 69 109 6.66
Other Current Liabilities		 13 78 52 29 24 22 22
Total Noncurrent Liabilities		 26 104 434 385 273 188 146
Long-Term Debt		 - - - - - - 0.00
Noncurrent Deferred Revenue		 - 0.39 262 202 110 33 0.00
Other Noncurrent Operating Liabilities		 22 103 172 182 163 155 146
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -201 246 827 733 981 734 1,238
Total Preferred & Common Equity		 -201 246 827 733 981 734 1,238
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -201 246 827 733 981 734 1,238
Common Stock		 1.92 643 1,595 1,793 2,171 2,299 2,878
Retained Earnings		 -203 -398 -768 -1,057 -1,190 -1,567 -1,641
Accumulated Other Comprehensive Income / (Loss)		 0.02 -0.01 -0.05 -2.43 0.60 0.68 1.11

Quarterly Balance Sheets for Beam Therapeutics

This table presents Beam Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 1,350 1,332 1,354 1,291 1,360 1,261 1,171 1,467 1,391 1,311 1,481
Total Current Assets		 1,109 1,083 1,095 1,040 1,122 1,029 946 1,248 1,175 1,099 1,267
Cash & Equivalents		 157 250 226 169 288 293 230 528 282 268 288
Short-Term Investments		 938 810 847 846 807 715 696 692 868 807 923
Prepaid Expenses		 14 24 22 24 27 21 20 28 25 24 55
Plant, Property, & Equipment, net		 111 122 128 128 121 117 114 110 109 108 101
Total Noncurrent Assets		 130 127 131 123 117 114 112 110 107 104 113
Other Noncurrent Operating Assets		 130 127 131 123 117 114 112 110 107 104 113
Total Liabilities & Shareholders' Equity		 1,350 1,332 1,354 1,291 1,360 1,261 1,171 1,467 1,391 1,311 1,481
Total Liabilities		 636 571 542 512 446 407 380 344 344 345 316
Total Current Liabilities		 239 220 210 220 187 177 166 142 174 183 75
Short-Term Debt		 - - - - - - - - - 1.19 2.70
Accounts Payable		 7.02 14 6.89 3.18 2.79 4.43 3.81 7.70 11 9.55 12
Accrued Expenses		 39 38 38 42 86 67 52 30 41 42 39
Current Deferred Revenue		 160 143 139 153 72 85 89 85 106 110 0.30
Other Current Liabilities		 33 25 26 22 26 21 21 18 17 19 20
Total Noncurrent Liabilities		 397 351 333 291 259 230 214 202 170 163 242
Long-Term Debt		 - - - - - - - - - - 100
Noncurrent Deferred Revenue		 198 172 156 125 100 75 58 49 20 10 0.00
Other Noncurrent Operating Liabilities		 199 179 177 167 160 154 156 153 150 152 142
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 714 762 812 779 913 854 791 1,123 1,047 966 1,164
Total Preferred & Common Equity		 714 762 812 779 913 854 791 1,123 1,047 966 1,164
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 714 762 812 779 913 854 791 1,123 1,047 966 1,164
Common Stock		 1,738 1,916 2,050 2,114 2,203 2,235 2,266 2,799 2,825 2,856 2,901
Retained Earnings		 -1,019 -1,154 -1,237 -1,333 -1,289 -1,380 -1,476 -1,676 -1,778 -1,891 -1,736
Accumulated Other Comprehensive Income / (Loss)		 -4.67 -0.77 -2.02 -2.02 -0.92 -1.11 1.76 0.16 0.01 0.79 -1.07

Annual Metrics And Ratios for Beam Therapeutics

This table displays calculated financial ratios and metrics derived from Beam Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 33.33% 215,916.67% 17.51% 520.01% -83.18% 120.01%
EBITDA Growth		 0.00% -144.69% -90.39% 27.79% 32.12% -134.19% 12.68%
EBIT Growth		 0.00% -142.87% -89.44% 25.67% 35.44% -139.43% 11.02%
NOPAT Growth		 0.00% -76.65% -195.62% 13.76% 47.86% -135.47% 7.67%
Net Income Growth		 0.00% -148.44% -90.47% 22.00% 54.16% -184.28% 78.77%
EPS Growth		 0.00% 70.18% -37.71% 28.42% 58.35% -166.28% 82.31%
Operating Cash Flow Growth		 0.00% -32.97% 30.78% 133.99% -762.29% -132.75% 0.62%
Free Cash Flow Firm Growth		 0.00% 0.00% -650.28% 83.58% -732.64% -47.22% 0.16%
Invested Capital Growth		 0.00% -500.58% -156.72% -148.12% 39.49% 43.80% 96.47%
Revenue Q/Q Growth		 0.00% 0.00% 6,538.16% -33.75% 363.14% -81.83% 150.88%
EBITDA Q/Q Growth		 0.00% -53.80% 8.09% 8.54% 51.06% -112.68% 16.14%
EBIT Q/Q Growth		 0.00% -52.47% 7.66% 6.71% 49.89% -121.29% 17.39%
NOPAT Q/Q Growth		 0.00% -12.19% -6.13% -8.15% 55.69% -127.49% 17.71%
Net Income Q/Q Growth		 0.00% -53.25% 7.66% 8.36% 57.75% -162.37% 80.71%
EPS Q/Q Growth		 0.00% 39.36% 14.90% 5.28% 58.75% -189.87% 81.72%
Operating Cash Flow Q/Q Growth		 0.00% -7.28% 28.28% -75.92% 57.79% -155.69% -2.05%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -21.08% -154.84% 38.53% -66.23% -8.09%
Invested Capital Q/Q Growth		 0.00% -2,417.92% -33.40% 9.32% 11.83% 12.83% 96.16%
Profitability Metrics		 - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -433,172.22% -794,958.33% -700.67% -430.58% -47.14% -656.46% -266.59%
Operating Margin		 -417,522.22% -553,166.67% -757.01% -555.61% -46.73% -654.25% -274.57%
EBIT Margin		 -447,522.22% -815,179.17% -714.89% -452.19% -47.08% -670.36% -271.12%
Profit (Net Income) Margin		 -435,144.44% -810,800.00% -714.91% -474.54% -35.09% -593.13% -57.24%
Tax Burden Percent		 100.00% 100.00% 100.00% 111.11% 101.04% 100.01% 100.00%
Interest Burden Percent		 97.23% 99.46% 100.00% 94.45% 73.75% 88.47% 21.11%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -389.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -360.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 311.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -77.59% -112.32% -69.13% -37.06% -15.46% -43.94% -8.11%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -51.60% -64.38% -38.48% -19.56% -12.70% -33.22% -29.31%
Return on Assets (ROA)		 -50.18% -64.03% -38.49% -20.53% -9.46% -29.39% -6.19%
Return on Common Equity (ROCE)		 154.58% -14.41% -69.13% -37.06% -15.46% -43.94% -8.11%
Return on Equity Simple (ROE_SIMPLE)		 38.95% -79.24% -44.83% -39.41% -13.50% -51.36% 0.00%
Net Operating Profit after Tax (NOPAT)		 -53 -93 -275 -237 -124 -291 -269
NOPAT Margin		 -292,265.56% -387,216.67% -529.91% -388.93% -32.71% -457.98% -192.20%
Net Nonoperating Expense Percent (NNEP)		 -29.41% -52.52% -15.16% -5.10% -0.79% -8.41% 18.02%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -32.30% -12.59% -39.66% -21.64%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 114,183.33% 123,354.17% 110.37% 144.13% 30.93% 175.58% 81.45%
R&D to Revenue		 303,438.89% 429,912.50% 746.64% 511.48% 115.80% 578.67% 293.12%
Operating Expenses to Revenue		 417,622.22% 553,266.67% 857.01% 655.61% 146.73% 754.25% 374.57%
Earnings before Interest and Taxes (EBIT)		 -81 -196 -371 -275 -178 -426 -379
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -78 -191 -363 -262 -178 -417 -373
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 19.27 6.57 3.76 2.26 2.80 2.27
Price to Tangible Book Value (P/TBV)		 0.00 19.27 6.57 3.76 2.26 2.80 2.27
Price to Revenue (P/Rev)		 10,000.00 197,180.98 104.73 45.24 5.87 32.33 20.13
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 29.21 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 21,922.89 184,694.69 86.11 27.54 2.72 18.94 11.24
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 74.48 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.04 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.04 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.87 -1.12 -1.18 -1.31 -1.32 -1.19 -1.06
Leverage Ratio		 1.55 1.75 1.80 1.81 1.63 1.49 1.31
Compound Leverage Factor		 1.50 1.74 1.80 1.70 1.20 1.32 0.28
Debt to Total Capital		 4.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.22%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.22%
Long-Term Debt to Total Capital		 4.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 286.69% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -190.88% 100.00% 100.00% 100.00% 100.00% 100.00% 99.78%
Debt to EBITDA		 -0.06 0.00 0.00 0.00 0.00 0.00 -0.01
Net Debt to EBITDA		 1.12 0.00 0.00 0.00 0.00 0.00 3.34
Long-Term Debt to EBITDA		 -0.06 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.08 0.00 0.00 0.00 0.00 0.00 -0.01
Net Debt to NOPAT		 1.66 0.00 0.00 0.00 0.00 0.00 4.63
Long-Term Debt to NOPAT		 -0.08 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -1.06 11.66 4.37 1.76 2.32 0.88 5.60
Noncontrolling Interest Sharing Ratio		 299.22% 87.17% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 3.24 3.01 5.96 4.89 5.89 4.82 13.09
Quick Ratio		 3.15 2.93 4.52 4.82 5.79 4.67 12.85
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -25 -190 -31 -260 -382 -382
Operating Cash Flow to CapEx		 -575.20% -585.32% -141.57% 46.02% -442.30% -3,881.58% -2,308.99%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -21,102.94 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 -7,363.11 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -12,564.33 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.05 0.04 0.27 0.05 0.11
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.84 0.61 3.14 0.54 1.29
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 14 -54 -139 -345 -209 -117 -4.14
Invested Capital Turnover		 0.00 0.00 -0.54 -0.25 -1.37 -0.39 -2.30
Increase / (Decrease) in Invested Capital		 0.00 -68 -85 -206 136 91 113
Enterprise Value (EV)		 395 4,433 4,464 1,678 1,029 1,203 1,570
Market Capitalization		 180 4,732 5,430 2,756 2,219 2,054 2,813
Book Value per Share		 ($31.04) $4.24 $12.13 $10.41 $12.04 $8.86 $12.20
Tangible Book Value per Share		 ($31.04) $4.24 $12.13 $10.41 $12.04 $8.86 $12.20
Total Capital		 105 246 827 733 981 734 1,241
Total Debt		 4.41 0.00 0.00 0.00 0.00 0.00 2.71
Total Long-Term Debt		 4.41 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -87 -300 -966 -1,078 -1,190 -851 -1,242
Capital Expenditures (CapEx)		 13 16 47 49 34 8.95 15
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -26 -94 94 -209 -184 -155 -71
Debt-free Net Working Capital (DFNWC)		 65 206 1,060 869 1,005 696 1,174
Net Working Capital (NWC)		 65 206 1,060 869 1,005 696 1,172
Net Nonoperating Expense (NNE)		 26 102 96 52 8.99 86 -189
Net Nonoperating Obligations (NNO)		 -87 -300 -966 -1,078 -1,190 -851 -1,242
Total Depreciation and Amortization (D&A)		 2.58 4.85 7.38 13 -0.21 8.83 6.34
Debt-free, Cash-free Net Working Capital to Revenue		 -146,900.00% -390,362.50% 181.17% -342.80% -48.82% -243.49% -50.62%
Debt-free Net Working Capital to Revenue		 363,366.67% 858,266.67% 2,043.77% 1,426.96% 266.20% 1,095.88% 840.45%
Net Working Capital to Revenue		 363,366.67% 858,266.67% 2,043.77% 1,426.96% 266.20% 1,095.88% 838.51%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($4.19) ($5.77) ($4.13) ($1.72) ($4.58) ($0.81)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 62.42M 64.23M 70.02M 77.15M 82.31M 98.91M
Adjusted Diluted Earnings per Share		 $0.00 ($4.19) ($5.77) ($4.13) ($1.72) ($4.58) ($0.81)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 62.42M 64.23M 70.02M 77.15M 82.31M 98.91M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($4.19) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 46.73M 68.73M 72.40M 81.66M 83.69M 101.86M
Normalized Net Operating Profit after Tax (NOPAT)		 -53 -93 -275 -237 -124 -291 -269
Normalized NOPAT Margin		 -292,265.56% -387,216.67% -529.91% -388.93% -32.71% -457.98% -192.20%
Pre Tax Income Margin		 -435,144.44% -810,800.00% -714.91% -427.08% -34.73% -593.07% -57.24%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -41,181.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 -30,525.06 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 -46,382.22 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -35,726.28 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -3.22% -1.06% -2.38% -0.07% -0.48% 0.00% 0.00%

Quarterly Metrics And Ratios for Beam Therapeutics

This table displays calculated financial ratios and metrics derived from Beam Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 101,856,245.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 101,856,245.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -0.93
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 8.82% 1,478.04% -69.39% -41.48% -17.01% -90.49% 0.81% -28.08% -32.03% 279.52% 324.87%
EBITDA Growth		 -29.04% 470.48% -2.72% -8.27% 2.28% -165.04% -5.16% -7.69% -12.29% 80.96% 13.03%
EBIT Growth		 -25.55% 393.81% -3.85% -11.06% -0.01% -176.67% -7.77% -8.92% -13.66% 78.73% 11.83%
NOPAT Growth		 -18.58% 313.29% -5.26% -2.69% 1.63% -152.71% -14.55% -14.54% -19.07% 75.09% 10.12%
Net Income Growth		 12.31% 472.36% -2.29% -10.00% -0.60% -163.27% -10.74% -12.34% -16.61% 370.38% 12.93%
EPS Growth		 21.79% 453.70% 9.02% -2.78% 4.10% -157.07% -2.48% 9.91% 5.98% 332.11% 26.02%
Operating Cash Flow Growth		 -20.52% 295.22% 9.17% 1.96% 1.85% -156.54% -4.15% 7.90% 7.54% -9.07% -23.71%
Free Cash Flow Firm Growth		 -203.45% -102.27% -15.15% -2.64% 19.48% -4,857.85% 11.62% 25.49% 34.65% 19.13% -35.65%
Invested Capital Growth		 37.77% 39.49% 39.23% 41.05% 43.16% 43.80% 46.53% 32.81% 19.83% 96.47% 157.51%
Revenue Q/Q Growth		 -14.53% 1,739.07% -97.66% 58.87% 21.21% 110.72% -75.16% 13.33% 14.55% 1,076.62% -72.19%
EBITDA Q/Q Growth		 -14.36% 225.24% -185.82% 5.47% -3.21% 16.64% -29.31% 3.20% -7.60% 84.36% -429.47%
EBIT Q/Q Growth		 -14.84% 221.43% -183.66% 4.81% -3.42% 6.91% -17.60% 3.79% -7.89% 82.57% -383.59%
NOPAT Q/Q Growth		 -5.99% 275.30% -154.86% -0.73% -1.53% 6.07% -19.24% -0.73% -5.54% 80.35% -330.21%
Net Income Q/Q Growth		 -16.08% 248.61% -169.10% 7.72% -6.17% 6.53% -20.94% 6.39% -10.20% 316.71% -138.61%
EPS Q/Q Growth		 -12.96% 256.56% -163.35% 8.26% -5.41% 6.84% -13.76% 19.35% -10.00% 330.00% -135.97%
Operating Cash Flow Q/Q Growth		 -6.04% 250.44% -173.85% 16.78% -6.16% 13.34% -36.04% 26.41% -6.58% -2.22% -54.30%
Free Cash Flow Firm Q/Q Growth		 -24.57% 98.52% -5,730.83% 4.78% 2.27% 8.63% -3.95% 19.73% 14.27% -13.06% -74.36%
Invested Capital Q/Q Growth		 9.51% 11.83% 13.18% 14.91% 12.74% 12.83% 17.39% -6.93% -4.11% 96.16% 1,445.63%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -648.42% 44.16% -1,506.92% -896.64% -763.49% -302.03% -1,571.99% -1,342.65% -1,261.13% -16.77% -319.20%
Operating Margin		 -629.72% 42.02% -1,405.29% -891.06% -746.40% -332.71% -1,596.87% -1,419.22% -1,307.60% -15.29% -337.81%
EBIT Margin		 -632.73% 41.78% -1,491.47% -893.66% -762.46% -336.85% -1,594.47% -1,353.52% -1,274.81% -18.88% -328.27%
Profit (Net Income) Margin		 -558.88% 45.16% -1,331.57% -773.45% -677.47% -300.51% -1,462.78% -1,208.26% -1,162.38% 214.09% -297.18%
Tax Burden Percent		 100.00% 299.35% 0.00% 100.04% 100.00% 47.80% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 88.33% 36.11% 0.00% 86.51% 88.85% 186.63% 91.74% 89.27% 91.18% -1,133.94% 90.53%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -42.01% -15.46% -16.09% -17.17% -18.29% -43.94% -38.04% -41.94% -47.19% -8.11% -5.77%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -741.05%
Operating Return on Assets (OROA)		 -39.08% 11.27% -399.90% -240.96% -216.57% -16.69% -71.73% -61.51% -57.21% -2.04% -36.53%
Return on Assets (ROA)		 -34.52% 12.18% -357.02% -208.55% -192.43% -14.89% -65.80% -54.91% -52.16% 23.15% -33.07%
Return on Common Equity (ROCE)		 -42.01% -15.46% -16.09% -17.17% -18.29% -43.94% -38.04% -41.94% -47.19% -8.11% -5.77%
Return on Equity Simple (ROE_SIMPLE)		 -40.27% 0.00% -14.75% -16.74% -18.15% 0.00% -34.49% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -76 133 -73 -73 -75 -70 -84 -84 -89 -17 -75
NOPAT Margin		 -440.80% 42.02% -983.70% -623.74% -522.48% -232.90% -1,117.81% -993.45% -915.32% -15.29% -236.47%
Net Nonoperating Expense Percent (NNEP)		 -1.92% 0.88% -2.39% -1.69% -2.28% -1.99% -2.23% -1.69% -2.40% 25.01% -1.65%
Return On Investment Capital (ROIC_SIMPLE)		 - 13.54% - - - -9.55% -7.43% -8.03% -9.18% -1.41% -5.92%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 147.79% 13.68% 360.65% 251.67% 185.82% 95.32% 374.03% 317.26% 275.73% 28.29% 108.48%
R&D to Revenue		 581.92% 44.30% 1,144.64% 739.39% 660.58% 337.39% 1,322.84% 1,201.96% 1,131.87% 87.00% 329.33%
Operating Expenses to Revenue		 729.72% 57.98% 1,505.29% 991.06% 846.40% 432.71% 1,697.23% 1,519.55% 1,407.60% 115.24% 437.81%
Earnings before Interest and Taxes (EBIT)		 -109 132 -111 -105 -109 -101 -119 -115 -124 -22 -104
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -111 140 -112 -106 -109 -91 -117 -114 -122 -19 -101
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.45 2.26 2.95 2.26 2.55 2.80 1.46 1.63 2.54 2.27 2.08
Price to Tangible Book Value (P/TBV)		 2.45 2.26 2.95 2.26 2.55 2.80 1.46 1.63 2.54 2.27 2.08
Price to Revenue (P/Rev)		 23.36 5.87 7.46 5.47 5.78 32.33 25.71 28.38 44.08 20.13 14.80
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 23.68
Enterprise Value to Revenue (EV/Rev)		 10.90 2.72 4.43 2.61 3.13 18.94 6.52 9.29 24.80 11.24 8.04
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.09
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.09
Financial Leverage		 -1.41 -1.32 -1.29 -1.25 -1.24 -1.19 -1.14 -1.14 -1.14 -1.06 -1.02
Leverage Ratio		 1.77 1.63 1.61 1.57 1.57 1.49 1.39 1.40 1.41 1.31 1.29
Compound Leverage Factor		 1.56 0.59 0.00 1.36 1.39 2.79 1.27 1.25 1.29 -14.87 1.17
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.12% 0.22% 8.12%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.12% 0.22% 0.21%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7.91%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.88% 99.78% 91.88%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -0.29
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.42 3.34 3.10
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.28
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -0.40
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.29 4.63 4.26
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.39
Altman Z-Score		 1.33 3.03 3.12 2.13 2.21 1.85 1.93 1.83 2.82 6.40 3.81
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.72 5.89 5.99 5.81 5.69 4.82 8.81 6.75 6.02 13.09 16.99
Quick Ratio		 4.61 5.79 5.85 5.69 5.57 4.67 8.62 6.61 5.89 12.85 16.25
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -219 -3.26 -190 -181 -177 -161 -168 -135 -115 -131 -228
Operating Cash Flow to CapEx		 -1,129.64% 3,763.53% -4,091.35% -4,232.99% -5,588.14% -2,571.21% -3,389.36% -2,437.82% -1,626.00% -2,230.56% -5,757.75%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.06 0.27 0.27 0.27 0.28 0.05 0.05 0.05 0.04 0.11 0.11
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.68 3.14 2.97 2.87 2.90 0.54 0.55 0.53 0.50 1.29 1.56
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -237 -209 -181 -154 -134 -117 -97 -104 -108 -4.14 56
Invested Capital Turnover		 -0.26 -1.37 -1.51 -1.70 -1.89 -0.39 -0.46 -0.47 -0.46 -2.30 -7.97
Increase / (Decrease) in Invested Capital		 144 136 117 107 102 91 84 51 27 113 152
Enterprise Value (EV)		 889 1,029 1,598 920 1,093 1,203 414 560 1,381 1,570 1,318
Market Capitalization		 1,905 2,219 2,693 1,929 2,019 2,054 1,634 1,710 2,455 2,813 2,427
Book Value per Share		 $9.84 $12.04 $11.18 $10.38 $9.60 $8.86 $13.42 $10.41 $9.55 $12.20 $11.43
Tangible Book Value per Share		 $9.84 $12.04 $11.18 $10.38 $9.60 $8.86 $13.42 $10.41 $9.55 $12.20 $11.43
Total Capital		 779 981 913 854 791 734 1,123 1,047 967 1,241 1,267
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.19 2.71 103
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 100
Net Debt		 -1,015 -1,190 -1,095 -1,008 -926 -851 -1,220 -1,150 -1,074 -1,242 -1,109
Capital Expenditures (CapEx)		 7.95 3.59 2.44 1.96 1.58 2.97 3.07 3.14 5.01 3.73 2.23
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -196 -184 -160 -156 -146 -155 -114 -149 -158 -71 -17
Debt-free Net Working Capital (DFNWC)		 819 1,005 934 852 779 696 1,106 1,001 917 1,174 1,195
Net Working Capital (NWC)		 819 1,005 934 852 779 696 1,106 1,001 916 1,172 1,192
Net Nonoperating Expense (NNE)		 20 -9.94 26 18 22 20 26 18 24 -262 19
Net Nonoperating Obligations (NNO)		 -1,015 -1,190 -1,095 -1,008 -926 -851 -1,220 -1,150 -1,074 -1,242 -1,109
Total Depreciation and Amortization (D&A)		 -2.70 7.53 -1.15 -0.35 -0.15 10 1.68 0.92 1.33 2.41 2.88
Debt-free, Cash-free Net Working Capital to Revenue		 -240.68% -48.82% -44.35% -44.26% -41.89% -243.49% -179.12% -247.22% -283.28% -50.62% -10.10%
Debt-free Net Working Capital to Revenue		 1,004.46% 266.20% 258.93% 241.69% 222.88% 1,095.88% 1,739.70% 1,661.36% 1,646.61% 840.45% 728.67%
Net Working Capital to Revenue		 1,004.46% 266.20% 258.93% 241.69% 222.88% 1,095.88% 1,739.70% 1,661.36% 1,644.47% 838.51% 727.02%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.22) $1.91 ($1.21) ($1.11) ($1.17) ($1.09) ($1.24) ($1.00) ($1.10) $2.53 ($0.91)
Adjusted Weighted Average Basic Shares Outstanding		 79.02M 77.15M 81.70M 82.31M 82.41M 82.31M 87.98M 102.00M 102.57M 98.91M 103.26M
Adjusted Diluted Earnings per Share		 ($1.22) $1.91 ($1.21) ($1.11) ($1.17) ($1.09) ($1.24) ($1.00) ($1.10) $2.53 ($0.91)
Adjusted Weighted Average Diluted Shares Outstanding		 79.02M 77.15M 81.70M 82.31M 82.41M 82.31M 87.98M 102.00M 102.57M 98.91M 103.26M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 81.50M 81.66M 82.31M 82.42M 82.81M 83.69M 100.56M 101.16M 101.47M 101.86M 102.88M
Normalized Net Operating Profit after Tax (NOPAT)		 -76 93 -73 -73 -75 -70 -83 -84 -89 -12 -75
Normalized NOPAT Margin		 -440.80% 29.41% -983.70% -623.74% -522.48% -232.90% -1,117.55% -993.22% -915.32% -10.70% -236.47%
Pre Tax Income Margin		 -558.88% 15.09% 0.00% -773.12% -677.47% -628.67% -1,462.78% -1,208.26% -1,162.38% 214.09% -297.18%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.22% -0.48% -0.42% -0.27% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Beam Therapeutics’ latest quarter shows a company with a very strong cash position, but still heavily dependent on financing and investment income to fund large operating losses. In Q1 2026, Beam reported $31.7 million in revenue, but operating expenses of $139.0 million drove an operating loss of $107.2 million and a net loss of $94.3 million. The balance sheet remains solid, with $1.21 billion in cash, equivalents, and short-term investments against $316.4 million in total liabilities.

Over the last four years, the biggest trend is clear: revenue has been highly volatile, expenses have stayed elevated, and losses remain substantial despite occasional quarterly swings in net income. Beam’s financial profile is still typical of a clinical-stage biotech company: high research spending, recurring operating losses, and reliance on a large cash reserve to keep the pipeline moving.

  • Beam ended Q1 2026 with about $1.21 billion in cash, cash equivalents, and short-term investments, giving it substantial liquidity.
  • The company’s current assets of $1.27 billion far exceed current liabilities of $74.6 million, indicating a strong short-term balance sheet.
  • Debt levels are manageable relative to liquidity, with only $102.9 million in total debt combined versus more than $1.2 billion in liquid assets.
  • Operating revenue in Q1 2026 rose to $31.7 million, up from $7.5 million in Q1 2025 and $24.2 million in Q1 2023.
  • Investing activity contributed to cash preservation in Q1 2026, with $25.3 million in net cash from investing activities as investment maturities exceeded new purchases.
  • The company has consistently generated revenue, but it remains lumpy and unpredictable, ranging from $7.4 million in Q1 2023 to $114.1 million in Q4 2025.
  • Research and development spending remains the largest expense, at $104.5 million in Q1 2026, reflecting ongoing pipeline investment.
  • Beam’s balance sheet is still equity-heavy, with common equity of $1.16 billion and accumulated deficits of $1.74 billion in retained earnings.
  • The company has repeatedly used financing and capital markets activity to support operations, including large equity issuance in 2024 and earlier periods.
  • Beam reported a net loss of $94.3 million in Q1 2026, showing the business is still far from profitability.
  • Operating cash flow was negative $128.5 million in Q1 2026, meaning core operations continue to consume cash.
  • For full-year 2025, the company swung from a profit in Q4 2025 to losses in other quarters, highlighting how dependent results are on non-operating items.
  • R&D and SG&A combined to more than $139 million in Q1 2026, keeping the operating loss very wide.
  • Cash and investments declined from roughly $1.08 billion in Q3 2025 to $1.21 billion in Q1 2026 after large swings in quarter-to-quarter cash flow, underscoring ongoing burn risk.

Bottom line: Beam Therapeutics has a strong balance sheet and enough liquidity to fund its near-term pipeline, but the company is still burning cash at a high rate and has not established a durable path to profitability. For investors, the key question is whether future clinical or commercial progress can eventually turn those large research investments into consistent revenue and earnings growth.

06/15/26 07:50 AM ETAI Generated. May Contain Errors.

Beam Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Beam Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Beam Therapeutics' net income appears to be on an upward trend, with a most recent value of -$79.99 million in 2025, rising from -$78.33 million in 2019. The previous period was -$376.74 million in 2024. View Beam Therapeutics' forecast to see where analysts expect Beam Therapeutics to go next.

Beam Therapeutics' total operating income in 2025 was -$383.69 million, based on the following breakdown:
  • Total Gross Profit: $139.74 million
  • Total Operating Expenses: $523.44 million

Over the last 6 years, Beam Therapeutics' total revenue changed from $18 thousand in 2019 to $139.74 million in 2025, a change of 776,250.0%.

Beam Therapeutics' total liabilities were at $242.82 million at the end of 2025, a 34.4% decrease from 2024, and a 340.3% increase since 2019.

In the past 6 years, Beam Therapeutics' cash and equivalents has ranged from $37.22 million in 2019 to $559.99 million in 2021, and is currently $294.94 million as of their latest financial filing in 2025.

Over the last 6 years, Beam Therapeutics' book value per share changed from -31.04 in 2019 to 12.20 in 2025, a change of -139.3%.


Related Companies

Financial statements for NASDAQ:BEAM last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel